Intech Investment Management LLC Raises Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Intech Investment Management LLC raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 103.2% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 65,826 shares of the biopharmaceutical company’s stock after buying an additional 33,431 shares during the period. Intech Investment Management LLC owned approximately 0.06% of Catalyst Pharmaceuticals worth $1,374,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its holdings in shares of Catalyst Pharmaceuticals by 0.3% in the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock valued at $6,518,000 after purchasing an additional 952 shares in the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Catalyst Pharmaceuticals by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock valued at $740,000 after purchasing an additional 1,000 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 1,495 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Bank of America restated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Thursday, January 9th. Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, March 3rd. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, Stephens reiterated an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $32.50.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $24.23 on Friday. The firm has a market cap of $2.94 billion, a PE ratio of 20.53, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $24.64. The firm’s fifty day moving average is $22.39 and its two-hundred day moving average is $21.61.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of Catalyst Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the transaction, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.